Stocks Health care KTTA
NASDAQ · Health carePasithea Therapeutics Corp. (KTTA)
It posted a net loss of $21.3M. At June 30, 2026 it held $45.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Pasithea Therapeutics Corp.
- Net worth
- Pasithea Therapeutics Corp. has a market value (market cap) of $18.5M at the latest share price, and shareholders' equity of $49.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2022 revenue was $486.6K (+3,130.4% year on year), with a net loss of $13.9M.
- Cash flow
- In fiscal 2025 operations used $15.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Pasithea Therapeutics Corp.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Pasithea Therapeutics Corp. does
Pasithea Therapeutics Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KTTA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$20.4M | -$2.91 | n/a |
| 2024 | n/a | -$13.9M | -$12.69 | n/a |
| 2023 | n/a | -$16M | -$0.42 | -$12.8M |
| 2022 | $486.6K | -$13.9M | -$1.76 | -$14.7M |
| 2021 | $15.1K | -$2.2M | -$0.70 | -$3.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Pasithea Therapeutics Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 16, 2026Other event 8-K
- September 16, 2026Delisting notice 25-NSE
- September 9, 2026
- August 21, 2026
- August 14, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026
- August 7, 2026Proxy statement DEF 14A
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 29, 2026Preliminary proxy statement PRE 14A
Insider trades
What the people running Pasithea Therapeutics Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 17, 2026 | Coastlands Capital LP10% owner | Boughtindirect | 100,000 | $53K |
| November 28, 2025 | Leahy EmerDirector | Received as pay | 33,333 | $25K |
| November 28, 2025 | Dumesnil SimonDirector | Bought | 33,333 | $25K |
| November 28, 2025 | Marques TiagoChief Executive Officer, Director | Bought | 33,333 | $25K |
| November 28, 2025 | Schneiderman Daniel HChief Financial Officer | Received as pay | 26,667 | $20K |
| November 28, 2025 | Steinman LawrenceDirector | Bought | 133,333 | $100K |
Who owns KTTA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Coastlands Capital LP13G, passive with 4 related filers | 11.48% | July 1, 2026 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 9.99% | February 12, 2026 |
| Janus Henderson Group PLC13G, passive | 9.99% | December 8, 2025 |
| Vivo Opportunity Fund Holdings, L.P.13G, passive with 3 related filers | 9.99% | August 14, 2026 |
| Squadron Master Fund LP13G, passive with 3 related filers | 9.9% | February 17, 2026 |
| Funicular Funds, LP13G, passive with 2 related filers | 7.4% | April 22, 2026 |
| Opaleye Management Inc.13G, passive with 2 related filers | 6.14% | July 31, 2026 |
| Stonepine Capital Management, LLC13G, passive with 3 related filers | 5.8% | June 23, 2026 |
Largest institutional holders
Insiders
6 insiders reported holding 4,203,893 shares in total, about $2.3M at the last price.
| Holder | Shares |
|---|---|
| Coastlands Capital LP10% owner | 3,835,0353,835,035 held indirectly |
| Steinman LawrenceDirector | 199,691 |
| Marques TiagoChief Executive Officer, Director | 73,334 |
| Dumesnil SimonDirector | 35,833 |
| Leahy EmerDirector | 33,333 |
| Schneiderman Daniel HChief Financial Officer | 26,667 |
Questions about KTTA
What does Pasithea Therapeutics Corp. do?
Pasithea Therapeutics Corp. is a company in the Health care sector, listed on NASDAQ as KTTA. Its shares trade on NASDAQ under the ticker KTTA.
What is Pasithea Therapeutics Corp.'s net worth?
Pasithea Therapeutics Corp. has a market value (market cap) of $18.5M at the latest share price, and shareholders' equity of $49.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Pasithea Therapeutics Corp. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $21.3M.
When did Pasithea Therapeutics Corp. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from September 16, 2026.
When is Pasithea Therapeutics Corp.'s next earnings report?
Pasithea Therapeutics Corp.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KTTA with
Follow KTTA
Get an email when Pasithea Therapeutics Corp. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pasithea Therapeutics Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.